Jove
Visualize
Contact Us

Related Concept Videos

Ultrasound II: Endoscopic Ultrasound and FibroScan01:25

Ultrasound II: Endoscopic Ultrasound and FibroScan

88
Endoscopic Ultrasound (EUS) and FibroScan are valuable diagnostic tools in gastroenterology and hepatology, each with specific applications and techniques.
Endoscopic Ultrasound (EUS):
88
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

604
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
604
Hepatic Drug Clearance: Restrictive and Nonrestrictive Clearance01:09

Hepatic Drug Clearance: Restrictive and Nonrestrictive Clearance

98
Hepatic clearance refers to the volume of blood cleared of a drug by the liver per unit of time. It plays a crucial role in drug metabolism and elimination. While hepatic clearance is commonly estimated by subtracting renal clearance from total body clearance, other pathways, such as pulmonary or biliary clearance, may also contribute. However, these pathways are generally less significant than hepatic and renal clearance.
Most drugs undergo restrictive clearance, which is proportional to the...
98
Hepatic Drug Clearance: Effect of Protein Binding01:09

Hepatic Drug Clearance: Effect of Protein Binding

171
Hepatic clearance is influenced by protein binding based on the drug's extraction ratio. Drugs with high extraction ratios are considered flow-limited and remain unaffected by protein binding during hepatic clearance. On the other hand, drugs with low extraction ratios may be impacted by plasma protein binding, although the extent of this influence depends on the fraction of the drug bound.
For low-extraction-ratio drugs that are less than 80% protein-bound, minor changes in protein binding...
171

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clinical and Psychological Outcomes After Monoclonal Gammopathy Screening: A Population-Based Screening Study and Subsequent Randomized Trial of Follow-Up.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Redefining light-chain smoldering multiple myeloma: prevalence and progression risk.

Leukemia·2026
Same author

Monoclonal gammopathy of undetermined significance is not associated with increased risk of skin cancer.

The British journal of dermatology·2026
Same author

HLA-B*44 Alleles and HLA-DQA1*03:01 as Genetic Risk Factors for Drug-Induced Liver Injury due to Fluoroquinolones.

Liver international : official journal of the International Association for the Study of the Liver·2026
Same author

An update on drug-induced liver injury-What's new?

Journal of internal medicine·2026
Same author

Editorial: The Role of Liver Biopsy in ANA Positive Subjects.

Alimentary pharmacology & therapeutics·2026
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Jun 16, 2025

Measurement of Liver Stiffness Using Atomic Force Microscopy Coupled with Polarization Microscopy
10:10

Measurement of Liver Stiffness Using Atomic Force Microscopy Coupled with Polarization Microscopy

Published on: July 20, 2022

3.8K

Clinically Important Decrease in Liver Stiffness Following Treatment for Hepatitis C: Outcome of the TraP HepC

Smári Freyr Kristjánsson1, Sigurdur Olafsson2, Magnús Gottfredsson1,3,4

  • 1Faculty of Medicine, University of Iceland, 101 Reykjavik, Iceland.

Journal of Clinical Medicine
|June 13, 2025
PubMed
Summary

Direct-acting antiviral therapy significantly reduced liver stiffness in 92% of patients cured of chronic hepatitis C. Persistent obesity and alcohol use were linked to increased liver stiffness, highlighting the need for ongoing risk factor management.

Keywords:
chronic hepatitis Chepatitis C virusliver cirrhosisliver stiffness

More Related Videos

Immunofluorescence to Monitor the Cellular Uptake of Human Lactoferrin and its Associated Antiviral Activity Against the Hepatitis C Virus
06:28

Immunofluorescence to Monitor the Cellular Uptake of Human Lactoferrin and its Associated Antiviral Activity Against the Hepatitis C Virus

Published on: October 1, 2015

13.4K
Author Spotlight: Advancing Hepatic Fibrosis Diagnosis Using Magnetic Resonance Elastography and AI
06:09

Author Spotlight: Advancing Hepatic Fibrosis Diagnosis Using Magnetic Resonance Elastography and AI

Published on: July 21, 2023

1.1K

Related Experiment Videos

Last Updated: Jun 16, 2025

Measurement of Liver Stiffness Using Atomic Force Microscopy Coupled with Polarization Microscopy
10:10

Measurement of Liver Stiffness Using Atomic Force Microscopy Coupled with Polarization Microscopy

Published on: July 20, 2022

3.8K
Immunofluorescence to Monitor the Cellular Uptake of Human Lactoferrin and its Associated Antiviral Activity Against the Hepatitis C Virus
06:28

Immunofluorescence to Monitor the Cellular Uptake of Human Lactoferrin and its Associated Antiviral Activity Against the Hepatitis C Virus

Published on: October 1, 2015

13.4K
Author Spotlight: Advancing Hepatic Fibrosis Diagnosis Using Magnetic Resonance Elastography and AI
06:09

Author Spotlight: Advancing Hepatic Fibrosis Diagnosis Using Magnetic Resonance Elastography and AI

Published on: July 21, 2023

1.1K

Area of Science:

  • Hepatology
  • Virology
  • Public Health

Background:

  • Direct-acting antiviral (DAA) therapy offers high cure rates for chronic hepatitis C (CHC).
  • Liver stiffness measurement (LSM) is used to assess liver fibrosis in CHC patients.
  • The Treatment as Prevention of Hepatitis C (TraP HepC) initiative in Iceland monitors CHC patients.

Purpose of the Study:

  • To evaluate changes in liver stiffness after DAA treatment for CHC.
  • To identify risk factors associated with hepatic fibrosis progression or regression.

Main Methods:

  • Retrospective analysis of CHC patients with baseline LSM > 9.5 kPa.
  • Follow-up LSM measurements, risk factor assessment (BMI, alcohol), and biochemical tests.
  • Comparison of baseline and follow-up liver stiffness values.

Main Results:

  • Median liver stiffness decreased from 17.2 kPa to 7.3 kPa post-treatment (p < 0.01).
  • 80% of patients with baseline cirrhosis (LSM > 12.5 kPa) regressed to non-cirrhotic levels.
  • High BMI and daily alcohol consumption correlated with increased liver stiffness in a subset of patients.

Conclusions:

  • Significant regression of liver stiffness was observed in 92% of CHC patients cured by DAAs.
  • Persistent risk factors like obesity and alcohol abuse are associated with elevated liver stiffness even after viral cure.
  • Comprehensive management of risk factors is crucial for long-term liver health in CHC survivors.